Fort Washington Investment Advisors Inc. OH Increases Holdings in Medtronic PLC $MDT

Fort Washington Investment Advisors Inc. OH lifted its stake in shares of Medtronic PLC (NYSE:MDT) by 1.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,605,343 shares of the medical technology company’s stock after purchasing an additional 43,746 shares during the quarter. Medtronic accounts for about 1.3% of Fort Washington Investment Advisors Inc. OH’s holdings, making the stock its 15th largest position. Fort Washington Investment Advisors Inc. OH owned about 0.20% of Medtronic worth $250,269,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Baker Tilly Wealth Management LLC increased its position in shares of Medtronic by 3.3% during the fourth quarter. Baker Tilly Wealth Management LLC now owns 3,221 shares of the medical technology company’s stock valued at $309,000 after buying an additional 102 shares during the period. Riverbend Wealth Management LLC boosted its position in shares of Medtronic by 3.2% in the third quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company’s stock valued at $332,000 after acquiring an additional 107 shares during the period. Holistic Financial Partners grew its stake in Medtronic by 3.0% during the third quarter. Holistic Financial Partners now owns 3,697 shares of the medical technology company’s stock valued at $352,000 after acquiring an additional 109 shares in the last quarter. Wynn Capital LLC grew its stake in Medtronic by 2.4% during the third quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company’s stock valued at $442,000 after acquiring an additional 110 shares in the last quarter. Finally, Meridian Investment Counsel Inc. increased its holdings in Medtronic by 0.4% during the 3rd quarter. Meridian Investment Counsel Inc. now owns 28,268 shares of the medical technology company’s stock worth $2,692,000 after acquiring an additional 110 shares during the period. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.26% of the company’s stock.

Medtronic Stock Performance

Medtronic stock opened at $87.72 on Friday. The firm’s fifty day moving average price is $95.99 and its 200-day moving average price is $96.52. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The stock has a market cap of $112.62 billion, a P/E ratio of 24.43, a price-to-earnings-growth ratio of 2.26 and a beta of 0.71. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date is Friday, March 27th. Medtronic’s dividend payout ratio is presently 79.11%.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Needham reaffirmed a Buy on MDT with a $120 price target, highlighting confidence in Medtronic’s multi‑year growth story and tuck‑in acquisition strategy, which supports upside expectations. Needham Reiterates Buy
• Positive Sentiment: FDA expanded the indication for the OmniaSecure defibrillation lead to allow placement in the left bundle branch area, broadening use for conduction‑system pacing and potentially increasing adoption in cardiac device procedures. OmniaSecure FDA Approval
• Positive Sentiment: Medtronic expanded its pain portfolio via a distribution agreement with Merit Medical to offer the FDA‑cleared ViaVerte basivertebral nerve ablation system — a minimally invasive, implant‑free option for chronic low‑back pain that can drive incremental sales in pain management. ViaVerte Distribution Deal
• Positive Sentiment: Market commentary reiterates the planned spin‑off of Medtronic’s high‑growth diabetes unit later this year — a strategic move investors view as value‑unlocking by creating a pure‑play diabetes company and a leaner core medtech business. Spin-Off Thesis
• Neutral Sentiment: Analyst coverage and articles (Zacks, TipRanks, others) largely frame recent news as mixed but keep consensus sentiment constructive — analysts expect multi‑year EPS growth despite the recent charge. Analyst Commentary
• Negative Sentiment: Medtronic cut FY‑2026 guidance after taking a charge tied to MiniMed approval and private equity considerations; this near‑term hit to earnings outlook is the primary reason shares are down as investors reassess short‑term profitability. Guidance Cut / MiniMed Charge

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. JPMorgan Chase & Co. cut their price target on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, February 18th. Daiwa Securities Group decreased their price target on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Barclays reiterated an “overweight” rating and issued a $118.00 price objective on shares of Medtronic in a research report on Wednesday, February 18th. Robert W. Baird reduced their target price on Medtronic from $103.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 18th. Finally, Sanford C. Bernstein upped their target price on Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a research note on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $110.74.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).